ECSP055818A - Métodos y composiciones para inducir apoptosis en células de cáncer. - Google Patents

Métodos y composiciones para inducir apoptosis en células de cáncer.

Info

Publication number
ECSP055818A
ECSP055818A EC2005005818A ECSP055818A ECSP055818A EC SP055818 A ECSP055818 A EC SP055818A EC 2005005818 A EC2005005818 A EC 2005005818A EC SP055818 A ECSP055818 A EC SP055818A EC SP055818 A ECSP055818 A EC SP055818A
Authority
EC
Ecuador
Prior art keywords
cancer cells
compositions
methods
induce apoptosis
apoptosis
Prior art date
Application number
EC2005005818A
Other languages
English (en)
Inventor
Marc Nasoff
Quinn L Deveraux
Deborah A Knee
Pedro Aza-Blanc
Garret M Hampton
Klaus Wagner
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of ECSP055818A publication Critical patent/ECSP055818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
    • C12Q2525/10—Modifications characterised by
    • C12Q2525/207—Modifications characterised by siRNA, miRNA

Abstract

Anticuerpos agonistas anti-DR4 o anti-DR5, combinados con agentes inductores de la apoptosis, inducen sigérgicamente apoptosis en células de cáncer.
EC2005005818A 2002-11-27 2005-05-26 Métodos y composiciones para inducir apoptosis en células de cáncer. ECSP055818A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42984202P 2002-11-27 2002-11-27
US44896003P 2003-02-21 2003-02-21
US49471403P 2003-08-12 2003-08-12
US50490103P 2003-09-22 2003-09-22

Publications (1)

Publication Number Publication Date
ECSP055818A true ECSP055818A (es) 2006-01-27

Family

ID=32475709

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005818A ECSP055818A (es) 2002-11-27 2005-05-26 Métodos y composiciones para inducir apoptosis en células de cáncer.

Country Status (17)

Country Link
US (2) US7229617B2 (es)
EP (1) EP1576179B1 (es)
JP (1) JP2006514096A (es)
KR (3) KR100915257B1 (es)
AT (1) ATE481092T1 (es)
AU (1) AU2003297579A1 (es)
BR (1) BR0316737A (es)
CA (1) CA2507077A1 (es)
CO (1) CO5640147A2 (es)
DE (1) DE60334247D1 (es)
EC (1) ECSP055818A (es)
MX (1) MXPA05005726A (es)
NO (1) NO20052922L (es)
PL (1) PL210174B1 (es)
PT (1) PT1576179E (es)
RU (1) RU2379056C2 (es)
WO (1) WO2004050895A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
NZ532881A (en) * 2001-12-20 2008-04-30 Human Genome Sciences Inc Antibodies that immunospecifically bind to trail receptors
BR0316737A (pt) * 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
CA2560742A1 (en) * 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
US20060115453A1 (en) * 2004-11-12 2006-06-01 Yaffe Michael B Methods and compositions for treating cellular proliferative diseases
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
EP1863512A1 (en) * 2005-03-24 2007-12-12 Irm, Llc Enhancing myc-dependent sensitivity of cancer to dr5 agonists
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007025231A2 (en) * 2005-08-26 2007-03-01 The Trustees Of The University Of Pennsylvania Methods using snail transcriptional repressor
BRPI0617751A2 (pt) * 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
ES2388932T3 (es) * 2005-12-02 2012-10-19 Genentech, Inc. Polipéptidos de unión y usos de los mismos
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
GB0606096D0 (en) * 2006-03-27 2006-05-03 Cbmm Sa Screening method
CN101535300B (zh) * 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
TWI389895B (zh) * 2006-08-21 2013-03-21 Infinity Discovery Inc 抑制ｂｃｌ蛋白質與結合夥伴間之交互作用的化合物及方法
WO2008066854A2 (en) * 2006-11-28 2008-06-05 Novartis Ag Methods and compositions for inducing apoptosis in cancer cells
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
TW200911835A (en) * 2007-06-08 2009-03-16 Irm Llc Methods and compositions for inducing apoptosis in cancer cells
CA2691251A1 (en) * 2007-06-19 2008-12-24 Yoshikazu Ohta Preventive/remedy for cancer
WO2009001224A2 (en) 2007-06-22 2008-12-31 Eth Zurich Antivirals
US9295736B2 (en) 2007-09-24 2016-03-29 Bar Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
US20110117081A1 (en) * 2008-05-05 2011-05-19 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
CA2728933A1 (en) * 2008-06-27 2009-12-30 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
JP2012502994A (ja) * 2008-09-22 2012-02-02 アムジエン・インコーポレーテツド 治療方法
CA2745775A1 (en) * 2008-12-18 2010-07-15 Centre National De La Recherche Scientifique - Cnrs- Method for identifying genes involved in trail-induced apoptosis and therapeutic applications thereof
CA2780130A1 (en) 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US9238069B2 (en) 2009-12-16 2016-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of death receptor ligands in cancer treatment
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
EP2560658B1 (en) * 2010-04-21 2017-02-22 VentiRx Pharmaceuticals, Inc. Enhancing antibody-dependent cellular cytotoxicity
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
JP2014501235A (ja) 2010-12-13 2014-01-20 ノバルティス アーゲー 二量体ｉａｐ阻害剤
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
US20140187604A1 (en) * 2011-05-03 2014-07-03 Dana-Farber Cancer Institute, Inc. Therapeutic and diagnostic target gene in acute myeloid leukemia
RU2488408C1 (ru) * 2012-03-22 2013-07-27 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) Средство и способ индукции апоптоза опухолевых клеток
UA118028C2 (uk) * 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
US10501552B2 (en) 2015-01-26 2019-12-10 Macrogenics, Inc. Multivalent molecules comprising DR5-binding domains
WO2017139485A1 (en) 2016-02-09 2017-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of sensitizing cancer cells to the cytotoxic effects of apoptosis inducing ligands in cancer treatment
CN109810194B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用
CN109810193B (zh) * 2017-11-21 2020-11-03 深圳市中科艾深医药有限公司 抗dr5的抗体及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
DE69128362T2 (de) 1990-06-01 1998-05-20 Chiron Corp Zusammensetzungen und verfahren zur identifizierung von molekülen mit biologischer wirksamkeit
WO1995030642A1 (en) 1994-05-06 1995-11-16 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AUPQ599500A0 (en) 2000-03-02 2000-03-23 Walter And Eliza Hall Institute Of Medical Research, The Novel peptides, modulatory agents therefor and methods of using them
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7279160B2 (en) * 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
CA2420534A1 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
ES2357225T3 (es) * 2001-11-01 2011-04-20 Uab Research Foundation Combinaciones de anticuerpos anti-dr5 y anticuerpos anti-dr4 y otros agentes terapéuticos.
BRPI0213846B8 (pt) * 2001-11-01 2021-05-25 Uab Research Foundation composição que compreende um anticorpo que liga especificamente uma dr5 do receptor de trail e um ou mais agentes terapêuticos
BR0316737A (pt) 2002-11-27 2005-12-13 Irm Llc Métodos e composições para induzir apoptose em células cancerosas
WO2005114187A2 (en) 2004-04-23 2005-12-01 The United States Of America As Represented By Thesecretary, Department Of Health And Human Services Methods and compositions for diagnosing aids and other diseases and conditions involving immune system activation
EP1778879A4 (en) 2004-06-21 2010-02-24 Univ Washington WEST NILE ANTI-VIRUS ANTIBODIES: THERAPEUTIC AND PROPHYLACTIC USES
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .

Also Published As

Publication number Publication date
MXPA05005726A (es) 2005-08-16
US20050079172A1 (en) 2005-04-14
AU2003297579A1 (en) 2004-06-23
US20070128204A1 (en) 2007-06-07
RU2005120167A (ru) 2006-03-10
JP2006514096A (ja) 2006-04-27
DE60334247D1 (de) 2010-10-28
RU2379056C2 (ru) 2010-01-20
KR100915257B1 (ko) 2009-09-03
WO2004050895A2 (en) 2004-06-17
EP1576179A2 (en) 2005-09-21
KR20070122578A (ko) 2007-12-31
NO20052922D0 (no) 2005-06-15
EP1576179A4 (en) 2007-06-06
EP1576179B1 (en) 2010-09-15
NO20052922L (no) 2005-08-17
KR20090046973A (ko) 2009-05-11
CO5640147A2 (es) 2006-05-31
CA2507077A1 (en) 2004-06-17
PL210174B1 (pl) 2011-12-30
ATE481092T1 (de) 2010-10-15
KR20050094811A (ko) 2005-09-28
BR0316737A (pt) 2005-12-13
US7229617B2 (en) 2007-06-12
PL377726A1 (pl) 2006-02-06
WO2004050895A3 (en) 2005-12-08
US8173128B2 (en) 2012-05-08
PT1576179E (pt) 2010-12-21

Similar Documents

Publication Publication Date Title
ECSP055818A (es) Métodos y composiciones para inducir apoptosis en células de cáncer.
HN2005029978A (es) Formulaciones
CY1122522T1 (el) Μετα αρσενικωδες νατριο για χρηση στην αγωγη του πολλαπλου μυελωματος
AR048819A1 (es) Metodos sinergicos y composiciones para el tratamiento del cancer
BRPI0511396A (pt) derivados de retinal e métodos para uso no tratamento de enfermidades visuais
TW200501960A (en) Synergistic kits and compositions for treating cancer
MX2008016453A (es) Composiciones y metodos para tratar infecciones parasitas.
ECSP056132A (es) Combinaciones para el tratamiento de enfermedades que implican proliferación, migración o apoptosis celulares de células de mieloma, o angiogénesis
UY30492A1 (es) Anticuerpo antagonista para el tratamiento del cancer
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
GT200600520A (es) Agentes antibacterianos
CL2008003122A1 (es) Uso de un anticuerpo anti-cd20 de tipo ii util para preparar un medicamento para tratar un cancer que expresa cd20 en combinacion con un inhibidor de proteasoma, composicion farmaceutica que contiene dicha combinacion y kit del mismo
TW200738263A (en) ANG2 and VEGF inhibitor combinations
DE60028971D1 (de) Apo-2l rezeptor-agonist und cpt-11 synergie-effekt
TW200510413A (en) Novel pyrrolodihydroisoquinolines
MX2009010066A (es) Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer.
ECSP109878A (es) Anticuerpos anti-cd79b e inmunoconjugados y métodos de uso de los mismos
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
BRPI0909227A2 (pt) uso de um anticorpo anti-cd20 tipo ii com aumentada citotoxicidade celular dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não hodgkin.
WO2006137934A3 (en) Purposeful movement of human migratory cells away from an agent source
CR9853A (es) Compuestos de exemestano (s)-6-metiloxaalquilo y metodos relacionados con su utilizacion
HK1107778A1 (en) Sodium stibogluconate and il-2 for treating cancer
WO2006075012A3 (en) Pyrrolodihydroisoquinolines as antiproliferative agents
RS52668B (en) ANTITUMOR EFFECT, ANTI-TUMOR AND ANALYSIS PROCESS